Holen Sie sich die Stockscreener-App
14.97
0.93%
-0.065
Schlusskurs vom Vortag:
$15.04
Offen:
$14.78
24-Stunden-Volumen:
79,322
Relative Volume:
0.43
Marktkapitalisierung:
$657.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.83%
1M Leistung:
+2.69%
6M Leistung:
+25.53%
1J Leistung:
+0.00%
1-Tages-Spanne:
$14.27
$15.45
1-Wochen-Bereich:
$14.16
$16.40
52-Wochen-Spanne:
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Vergleichen Sie MAZE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
15.00 | 659.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.40 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.84 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.85 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
747.84 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.47 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
Risk vs reward if holding onto Maze Therapeutics Inc.Market Activity Report & Safe Investment Capital Preservation Plans - Newser
Will Maze Therapeutics Inc. benefit from sector rotationEarnings Trend Report & Real-Time Market Sentiment Reports - khodrobank.com
What is Maze Therapeutics Inc.’s book value per share2025 Bull vs Bear & Stepwise Entry and Exit Trade Signals - khodrobank.com
Is Maze Therapeutics Inc. showing signs of accumulation2025 Biggest Moves & AI Powered Buy and Sell Recommendations - Newser
Entry Recap: Is Maze Therapeutics Inc. a cyclical or defensive stockMarket Trend Report & Verified Momentum Watchlists - khodrobank.com
Should you wait for a breakout in Maze Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Maze Therapeutics Inc. stock chart pattern explainedPortfolio Profit Report & Daily Chart Pattern Signal Reports - Newser
Custom strategy builders for tracking Maze Therapeutics Inc.M&A Rumor & Consistent Growth Stock Picks - Newser
Sentiment analysis tools applied to Maze Therapeutics Inc.Portfolio Value Report & Intraday High Probability Setup Alerts - Newser
Using data models to predict Maze Therapeutics Inc. stock movementStop Loss & Precise Swing Trade Alerts - Newser
Understanding Maze Therapeutics Inc.’s price movementOptions Play & Daily Profit Focused Stock Screening - Newser
What MACD and RSI say about Maze Therapeutics Inc.2025 Valuation Update & Real-Time Stock Movement Alerts - Newser
What indicators show strength in Maze Therapeutics Inc.July 2025 Setups & AI Enhanced Trading Signals - Newser
Statistical indicators supporting Maze Therapeutics Inc.’s strengthBreakout Watch & Weekly High Return Stock Forecasts - Newser
Maze Therapeutics Inc. stock volume spike explained2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - Newser
Can Maze Therapeutics Inc. grow without dilutionDividend Hike & Verified Technical Signals - khodrobank.com
Multi asset correlation models including Maze Therapeutics Inc.Risk Management & Weekly Chart Analysis and Guides - Newser
Maze Therapeutics’ Claims For Unapproved Kidney Disease Drug Face Regulatory Scrutiny - insights.citeline.com
Should value investors consider Maze Therapeutics Inc.July 2025 Levels & Growth Focused Stock Reports - khodrobank.com
Is it too late to sell Maze Therapeutics Inc.Market Growth Report & Breakout Confirmation Trade Signals - Newser
Visual analytics tools that track Maze Therapeutics Inc. performanceProduct Launch & Free Reliable Trade Execution Plans - Newser
Maze Therapeutics appoints Misbah Tahir as chief financial officer - Investing.com India
Maze Therapeutics initiated with a Buy at BTIG - TipRanks
BTIG initiates coverage on Maze Therapeutics with a Buy rating and PT of $30. - AInvest
Maze Therapeutics appoints Tahir as Chief Financial Officer - TipRanks
Maze Therapeutics Appoints Misbah Tahir as CFO - TipRanks
Maze Therapeutics Appoints Misbah Tahir as New CFO - AInvest
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewswire
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewswire Inc.
BTIG Initiates Maze Therapeutics at Buy With $30 Price Target - MarketScreener
Is Maze Therapeutics Inc. stock showing strong momentum2025 Institutional Moves & Technical Pattern Recognition Alerts - khodrobank.com
How to monitor Maze Therapeutics Inc. with trend dashboardsWeekly Trend Recap & Real-Time Buy Signal Alerts - Newser
Can Maze Therapeutics Inc. outperform in the next rallyLayoff News & Community Verified Trade Signals - khodrobank.com
Will Maze Therapeutics Inc. stock recover after earningsWeekly Investment Recap & AI Driven Stock Movement Reports - khodrobank.com
Maze Therapeutics Inc. Breakout Confirmed by Volume Metrics getLinesFromResByArray error: size == 0 - 강소기업뉴스
Institutional scanner results for Maze Therapeutics Inc.2025 Top Gainers & Technical Confirmation Trade Alerts - Newser
Historical volatility pattern of Maze Therapeutics Inc. visualizedTrade Signal Summary & Real-Time Volume Triggers - Newser
Can trapped investors hope for a rebound in Maze Therapeutics Inc.2025 Earnings Impact & Daily Volume Surge Trade Alerts - Newser
Will Maze Therapeutics Inc. benefit from seasonality getLinesFromResByArray error: size == 0 - sisain.net
Maze Therapeutics Inc. Approaches Psychological Resistance Level getLinesFromResByArray error: size == 0 - 뉴스영
Is it time to cut losses on Maze Therapeutics Inc.2025 Analyst Calls & AI Driven Stock Reports - Newser
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):